NCT06778902Not yet recruitingPhase 2
AZA Combined with R-GemOx for Elderly DLBCL Patients
AZA Combined with R-GemOx for the Initial Treatment of Elderly DLBCL: an Open, Single-arm, Multicenter Clinical Study
Source: ClinicalTrials.gov · Last updated 16 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in elderly diffuse large B-cell lymphoma (DLBCL) patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 7 Jan 2025
- Start date
- 1 Feb 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06778902
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 1 Feb 2025 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patients have contraindications to any drug in the combined treatment.
Other illness
- Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.
Other
- DLBCL combined with other types of lymphoma. Transformed DLBCL.
- DLBCL with central nervous system invasion.
- Mentally ill persons or persons unable to obtain informed consent.
- The investigators think that the patient is not suitable for the study.
Who the study is looking for
- Subjects fully understand and voluntarily participate in this study and sign informed consent.
- Aged ≥60 years, both male and female.
- Pathologically confirmed DLBCL
- There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
- No previous chemotherapy or radiotherapy for DLBCL has been received.
- Expected survival ≥3 months.
Age in the registry: 60 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Daping Hospital, Third Military Medical University (Army Medical University) Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.